Skip to content
DataLookout
Menu

NCT07887984

Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Proportion of patients who are classified as being MRD-negative post-consolidation (Phase II)
Timeframe: Up to 1 year from registration
Progression-free survival (PFS) (Phase III)
Timeframe: From date of randomization to the date of documented disease progression and/or death due to any cause, whichever comes first, assessed up to 20 years

Secondary (17)

Overall survival (OS) (Phase II)
ate of conversion from MRD-positive to MRD-negative post-induction to post-consolidation in each treatment arm (Phase II)
Overall rate of MRD-negativity in each treatment arm (Phase II)
Rate of MRD-negativity after 2 years of maintenance in each treatment arm (Phase II)
Rate of grade 3+ adverse events in each treatment arm (Phase II)
Show 12 moreShow less
Rate of grade 3+ serious infection in each treatment arm (Phase II)
Progression-free survival (PFS) (Phase II)
Overall response rate in each treatment arm (Phase II)
Rate of grade 3+ serious infection in each treatment arm (Phase III)
Overall survival (OS) (Phase III)
Rate of MRD-negative post-consolidation in each treatment arm (Phase II)
Overall rate of MRD-negativity in each treatment arm (Phase III)
Rate of MRD-negativity after 2 years of maintenance in each treatment arm (Phase III)
Rate of conversion from MRD-positive to MRD-negative post-induction to post-consolidation in each treatment arm (Phase III)
Rate of sustained MRD-negativity (Phase III)
Rate of grade 3+ adverse events in each treatment arm (Phase III)
Overall response rate in each treatment arm (Phase III)

Arms and interventions

Phase II Arm 1 (DaraRVd, ASCT, melphalan)Active comparator

INDUCTION: Patients receive the DaraRVd regimen consisting of: 1) daratumumab and recombinant human hyaluronidase SC on days 1, 8, and 15 of each cycle; 2) lenalidomide PO on days 1-14 of each cycle; 3) bortezomib SC on days 1, 4, 8, and 11 of each cycle; and 4) dexamethasone PO or IV on days 1, 4, 8, 11, and 15 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients undergo ASCT and receive melphalan IV on a single day or on two consecutive days. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Phase II Arm 2 (DaraRVd, teclistamab)Experimental

INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Phase II Arm 3 (DaraRVd, talquetamab)Experimental

INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive talquetamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Phase II Arm 4 (DaraRVd, teclistamab, talquetamab)Experimental

INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab SC and talquetamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Phase III Arm 1 (DaraRVd, ASCT, melphalan)Active comparator

INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients undergo ASCT and receive melphalan as in Phase II Arm 1. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Phase III Arm 2 (DaraRVd, teclistamab, talquetamab)Experimental

INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab alone as in Phase II Arm 2, talquetamab alone as in Phase II Arm 3, or teclistamab and talquetamab together as in Phase II Arm 4. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.

Drugs: Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib, Dexamethasone, Melphalan, Teclistamab

Procedures: Autologous Hematopoietic Stem Cell Transplantation, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Magnetic Resonance Imaging

Biologicals: Talquetamab